Q32 Bio Launches with $46 Million and IL-7 Inhibitor Licensed from BMS

With $46 million in Series A financing, Cambridge, Mass.-based Q32 Bio, with a focus on healthy immune regulation, has emerged onto the scene with plans to enter its lead asset into the clinic later this year.